[New options in pharmacological treatment of urinary stress incontinence in women].
OBJECTIVE
The aim of this paper is to provide a brief update review of current pharmacological agents used to treat women with GSI (Genuine Stress Incontinence).


METHODS
Review article.


METHODS
Gynecological and Obstetric Clinic, 1. LF UK and VFN, Apolinárskã 18, Prague 2.


RESULTS
Genuine stress urinary incontinence is the involuntary loss of urine associated with increasing of intraabdominal pressure (such as running, jumping, coughing, etc.). Although the pelvic floor muscle training, behavioral and surgical therapies are currently the mainstay of treating GSI, we believe that pharmacological treatment can help to increase the cure rate. With the advent of duloxetine, a serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) reuptake inhibitor acting within the sacral spinal cord, the role of pharmacological treatment of GSI must be reviewed ev. re-examined.
Martan
A
A
Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha. martan@vfn.cz
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*
D018759:Adrenergic Uptake Inhibitors; D018765:Dopamine Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes